摘要:
The present invention relates to a gene/carrier complex having the effect of preventing or treating acute inflammatory disease, comprising a tumor necrosis factor-alpha converting enzyme (TACE) siRNA and a non-viral gene carrier, wherein the non-viral gene carrier comprises a TFA salt of TKPR-oligo-arginine.
摘要:
Disclosed is a gene/carrier complex for preventing or treating inflammatory diseases, including tumor necrosis factor-α converting enzyme (TNF-α converting enzyme, TACE) shRNA and a nonviral gene carrier, wherein the nonviral gene carrier includes an acetate of disulfide-linked poly(oligo-arginine) or a TFA salt of poly(oligo-aspartic acid)poly(oligo-arginine).
摘要:
Disclosed is a gene/carrier complex for preventing or treating inflammatory diseases, including tumor necrosis factor-α converting enzyme (TNF-α converting enzyme, TACE) shRNA and a nonviral gene carrier, wherein the nonviral gene carrier includes an acetate of disulfide-linked poly(oligo-arginine) or a TFA salt of poly(oligo-aspartic acid)poly(oligo-arginine).
摘要:
The present invention relates to a parenteral drug delivery carrier and a drug delivery system that use a thermosensitive gel based on methyl cellulose alone as a low molecular weight polysaccharide without a salting-out salt. The single use of the low molecular weight methyl cellulose as a natural polymer increases the biocompatibility and biodegradability of the drug delivery system. Therefore, the drug delivery system is suitable for use in the preparation of a sustained release composition for parenteral drug delivery.
摘要:
The present invention relates to a gene delivery system for targeting adipocytes and a treatment system for obesity and obesity-derived metabolic syndromes using the same and, more particularly, to a non-viral gene delivery system which directly targets a differentiated obesity (mature) adipocyte and contains an adipocyte targeting sequence (ATS)-arginine (R9) peptide.
摘要:
The present disclosure relates to: an adipocyte-targeting non-viral gene delivery complex comprising a sh(FABP4+FABP5) dual plasmid vector; and treatment for obesity and obesity-induced metabolic syndromes by using the same and, more particularly, to a gene delivery complex comprising: an adipocyte-targeting sequence; a nine-arginine (R9) peptide; and a dual plasmid vector comprising a gene for treatment of obesity and obesity-induced metabolic syndromes, wherein the gene for treatment of obesity and obesity-induced metabolic syndromes is a base sequence inhibiting the expression of a FABP4 gene and a FABP5 gene. According to the present disclosure, in order to treat obesity-related diseases, a dual plasmid vector capable of simultaneously inhibiting the FABP4 and FABP5 genes is produced, and this vector is bound to a predetermined delivery system that specifically delivers the vector into adipocytes so as to provide a gene delivery complex. In this way, it is possible to achieve an excellent therapeutic effect on obesity which targets only adipocytes without cytotoxicity.
摘要:
The present invention relates to a visceral adipose tissue macrophage-targeted non-viral gene/carrier complex for preventing and treating obesity-induced type II diabetes. More specifically, the gene/carrier complex according to the present invention delivers a therapeutic gene in a stable manner in a case of being injected into the body with the visceral adipose tissue macrophages being targeted, and thus exhibits an excellent inhibitory effect against TACE, which allows the gene/carrier complex to be applied for prevention or treatment of obesity-induced type II diabetes.
摘要:
The present invention relates to dual-targeting lipid-polymer hybrid nanoparticles (T-hNPs) comprising a polymer core comprising a heme oxygenase 1 inhibitor and a lipid membrane (shell) comprising a targeting moiety, a kit for preparing the dual-targeting lipid-polymer hybrid nanoparticles, a pharmaceutical composition comprising the dual-targeting lipid-polymer hybrid nanoparticles as an active ingredient, and a method of preventing or treating cancer comprising administering the pharmaceutical composition to a subject in need thereof. Accordingly, the present invention can provide the dual-targeting lipid-polymer hybrid nanoparticles (T-hNPs) comprising a polymer core comprising a heme oxygenase 1 inhibitor and a lipid membrane (shell) comprising a targeting moiety, the kit for preparing the dual-targeting lipid-polymer hybrid nanoparticles (T-hNPs), the pharmaceutical composition comprising the dual-targeting lipid-polymer hybrid nanoparticles (T-hNPs) as an active ingredient, and the method of preventing or treating cancer comprising administering the pharmaceutical composition to a subject in need thereof.
摘要:
The present invention relates to a parenteral bioactive substance delivery composition and a bioactive substance carrier using a micelle based on low molecular weight methyl cellulose with a weight average molecular weight of 6 to 9.5 kDa. The bioactive substance carrier according to the present invention can completely resolve a problem of excretion to outside the body which cannot be resolved by conventional low molecular weight methyl cellulose having a weight average molecular weight of 10 to 20 kDa to increase safety and form a micelle to enable the solubilization of poorly soluble drugs, and thus is expected to be very useful for sustained release parenteral drug delivery.
摘要:
The present invention relates to a gene delivery system which improves siRNA delivery and the in vivo systemic circulation efficiency thereof More particularly, the present invention is a siRNA gene delivery system for systemic circulation based on polyethylene glycol (PEG) and an arginine 9 (R9) peptide.